The partnership marks Shilpa Biologicals’ entry into the Latin American market and represents the first product under this strategic collaboration.
Also read: Standard Chartered announces $1.5 billion share repurchase as quarterly profit disappointsThe companies said the arrangement combines Shilpa’s biologics development and manufacturing capabilities with SteinCares’ regional commercial platform, which includes regulatory, market access and distribution expertise across more than 30 countries in Latin America and the Caribbean.
Dr Sridevi Khambhampaty, CEO of Shilpa Biologicals, said, “Through this licensing agreement, we are entering Latin America and aim to broaden
patient access to safe treatments across the region.””This collaboration reinforces our commitment to scalable, long-term global licensing partnerships and creates a strong platform for future collaborations across key international markets and our growing biosimilars portfolio,” she added.
Also read: PayPal draws buyer interest as stock rout erases nearly half its value
Mitchell Waserstein, CEO of SteinCares, said the agreement reinforces the company’s leadership in biosimilars. He added that by combining Shilpa’s “proven capabilities in biologics development and manufacturing” with their local expertise, “we are creating scalable healthcare opportunities and expanding access to innovative, cost-effective treatments across the region.”
Shilpa Biologicals focuses on immunology, oncology and ophthalmics, and operates as a hybrid CDMO and pharmaceutical company, offering development, manufacturing and ready-to-license products.
SteinCares specialises in the commercialisation of innovative medicines, biosimilars and complex generics across Latin America.
Shares of Shilpa Medicare Ltd were trading 1.22% down at ₹322.75 as of 10.58 am. The stock has gained 20.27% in the past month.
